Tandem Diabetes Care (TNDM) Stock Forecast, Price Target & Predictions
TNDM Stock Forecast
Tandem Diabetes Care stock forecast is as follows: an average price target of $84.44 (represents a 92.04% upside from TNDM’s last price of $43.97) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
TNDM Price Target
The average price target for Tandem Diabetes Care (TNDM) is $84.44 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $160.00 to $36.00. This represents a potential 92.04% upside from TNDM's last price of $43.97.
TNDM Analyst Ratings
According to 14 Wall Street analysts, Tandem Diabetes Care's rating consensus is 'Buy'. The analyst rating breakdown for TNDM stock is 0 'Strong Buy' (0.00%), 9 'Buy' (64.29%), 4 'Hold' (28.57%), 1 'Sell' (7.14%), and 0 'Strong Sell' (0.00%).
Tandem Diabetes Care Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | William Plovanic | Canaccord Genuity | $57.00 | $37.04 | 53.89% | 29.63% |
| Aug 05, 2024 | Matt Miksic | Barclays | $58.00 | $41.67 | 39.19% | 31.91% |
| Aug 02, 2024 | Matt O'Brien | Piper Sandler | $55.00 | $35.21 | 56.21% | 25.09% |
| Aug 02, 2024 | Jeff Johnson | Robert W. Baird | $39.00 | $35.21 | 10.76% | -11.30% |
| Jun 10, 2024 | Steven Lichtman | Oppenheimer | $58.00 | $47.03 | 23.33% | 31.91% |
| May 29, 2024 | Matthew Blackman | Stifel Nicolaus | $60.00 | $51.93 | 15.55% | 36.46% |
| May 22, 2024 | Brooks O'Neil | Lake Street | $75.00 | $49.32 | 52.07% | 70.57% |
| May 03, 2024 | Matt O'Brien | Piper Sandler | $50.00 | $36.56 | 36.76% | 13.71% |
| May 03, 2024 | Jeff Johnson | Robert W. Baird | $36.00 | $36.56 | -1.53% | -18.13% |
| Apr 29, 2024 | Lawrence Biegelsen | Wells Fargo | $45.00 | $37.55 | 19.84% | 2.34% |
The latest Tandem Diabetes Care stock forecast, released on Aug 08, 2024 by William Plovanic from Canaccord Genuity, set a price target of $57.00, which represents a 53.89% increase from the stock price at the time of the forecast ($37.04), and a 29.63% increase from TNDM last price ($43.97).
Tandem Diabetes Care Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 14 |
| Avg Price Target | - | $52.25 | $49.36 |
| Last Closing Price | $43.97 | $43.97 | $43.97 |
| Upside/Downside | -100.00% | 18.83% | 12.26% |
In the current month, the average price target of Tandem Diabetes Care stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Tandem Diabetes Care's last price of $43.97. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 22, 2024 | Morgan Stanley | - | Equal-Weight | Initialise |
| Aug 08, 2024 | Canaccord Genuity | - | Buy | Initialise |
| Aug 05, 2024 | Barclays | Overweight | Overweight | Hold |
| Aug 02, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 10, 2024 | Citigroup | Buy | Buy | Hold |
| Jun 10, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 22, 2024 | Lake Street | Buy | Buy | Hold |
| May 22, 2024 | Citigroup | Neutral | Buy | Upgrade |
| May 06, 2024 | Barclays | Overweight | Overweight | Hold |
| May 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Tandem Diabetes Care's last stock rating was published by Morgan Stanley on Aug 22, 2024. The company Initialise its TNDM rating from "null" to "Equal-Weight".
Tandem Diabetes Care Financial Forecast
Tandem Diabetes Care Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $281.49M | $290.10M | $169.38M | $220.50M | $204.55M | - | $175.91M | $210.00M | $179.63M | $172.14M | $141.04M | $168.06M | $123.60M | $109.24M | $97.93M | $108.40M | $94.66M |
| Avg Forecast | $312.83M | $282.12M | $277.56M | $250.87M | $277.85M | $249.32M | $244.88M | $220.81M | $251.46M | $223.71M | $205.63M | $174.52M | $203.49M | $192.76M | $197.62M | $170.31M | $221.00M | $207.60M | $205.21M | $168.21M | $199.01M | $171.37M | $143.37M | $121.95M | $141.59M | $115.33M | $87.15M | $84.79M | $109.22M | $89.14M |
| High Forecast | $314.48M | $283.61M | $279.02M | $252.19M | $279.32M | $250.64M | $246.17M | $221.97M | $252.78M | $224.78M | $206.72M | $175.44M | $211.85M | $200.65M | $198.66M | $171.21M | $222.17M | $208.69M | $205.21M | $177.99M | $210.57M | $181.33M | $151.71M | $129.03M | $149.82M | $122.04M | $92.22M | $89.72M | $115.56M | $94.32M |
| Low Forecast | $310.56M | $280.08M | $275.55M | $249.05M | $275.84M | $247.52M | $243.10M | $219.21M | $249.63M | $222.12M | $204.14M | $173.26M | $200.16M | $190.05M | $196.19M | $169.07M | $219.40M | $206.09M | $205.21M | $159.85M | $189.11M | $162.85M | $136.24M | $115.88M | $134.55M | $109.60M | $82.82M | $80.57M | $103.78M | $84.71M |
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 3 | 6 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.46% | 1.47% | 0.99% | 1.00% | 0.99% | - | 1.05% | 1.06% | 1.05% | 1.20% | 1.16% | 1.19% | 1.07% | 1.25% | 1.15% | 0.99% | 1.06% |
Tandem Diabetes Care's average Quarter revenue forecast for Dec 23 based on 6 analysts is $203.49M, with a low forecast of $200.16M, and a high forecast of $211.85M. TNDM's average Quarter revenue forecast represents a -27.71% decrease compared to the company's last Quarter revenue of $281.49M (Sep 23).
Tandem Diabetes Care EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 3 | 6 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-31.55M | $-38.81M | $29.68M | $-17.73M | $-42.77M | - | $-11.77M | $12.74M | $10.33M | $8.59M | $-598.00K | $24.99M | $-1.77M | $-23.76M | $-12.21M | $4.37M | $-1.28M |
| Avg Forecast | $-14.16M | $-12.77M | $-12.57M | $-11.36M | $-12.58M | $-11.29M | $-11.09M | $-10.00M | $-11.39M | $-10.13M | $-9.31M | $-1.42M | $-9.21M | $-8.73M | $-8.95M | $-1.29M | $-10.01M | $8.52M | $-9.29M | $-1.02M | $19.49M | $7.74M | $21.25M | $-807.30K | $23.06M | $-972.95K | $-13.38M | $-7.11M | $11.02M | $-2.02M |
| High Forecast | $-14.06M | $-12.68M | $-12.48M | $-11.28M | $-12.49M | $-11.21M | $-11.01M | $-9.93M | $-11.30M | $-10.06M | $-9.24M | $-1.14M | $-9.06M | $-8.60M | $-8.88M | $-1.03M | $-9.93M | $10.22M | $-9.29M | $-816.99K | $23.39M | $9.29M | $25.50M | $-645.84K | $27.67M | $-778.36K | $-10.71M | $-5.69M | $13.22M | $-1.62M |
| Low Forecast | $-14.24M | $-12.84M | $-12.63M | $-11.42M | $-12.65M | $-11.35M | $-11.15M | $-10.05M | $-11.45M | $-10.18M | $-9.36M | $-1.71M | $-9.59M | $-9.09M | $-8.99M | $-1.55M | $-10.06M | $6.82M | $-9.29M | $-1.23M | $15.59M | $6.20M | $17.00M | $-968.76K | $18.44M | $-1.17M | $-16.06M | $-8.53M | $8.82M | $-2.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.61% | 4.34% | -22.98% | 1.77% | -5.02% | - | 11.52% | 0.65% | 1.33% | 0.40% | 0.74% | 1.08% | 1.82% | 1.77% | 1.72% | 0.40% | 0.63% |
8 analysts predict TNDM's average Quarter EBITDA for Jun 23 to be $-8.95M, with a high of $-8.88M and a low of $-8.99M. This is -130.14% lower than Tandem Diabetes Care's previous annual EBITDA (Mar 23) of $29.68M.
Tandem Diabetes Care Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 3 | 6 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-32.96M | $-35.77M | $-123.87M | $-15.85M | $-48.97M | - | $-14.71M | $10.81M | $5.79M | $4.01M | $-5.04M | $17.00M | $-9.41M | $-27.11M | $-14.87M | $2.65M | $-2.90M |
| Avg Forecast | $-907.45K | $-11.58M | $-13.34M | $-21.18M | $-8.25M | $-18.37M | $-19.00M | $-26.50M | $-12.31M | $-26.67M | $-35.21M | $-11.99M | $-17.55M | $-31.15M | $-32.45M | $-10.90M | $-5.28M | $4.78M | $1.15M | $-8.61M | $13.38M | $4.35M | $9.92M | $-6.81M | $15.68M | $-5.17M | $-15.27M | $-8.66M | $6.68M | $-4.57M |
| High Forecast | $-898.90K | $-11.47M | $-13.22M | $-20.98M | $-8.17M | $-18.20M | $-18.82M | $-26.25M | $-12.19M | $-22.33M | $-34.88M | $-9.59M | $-11.44M | $1.83M | $-32.14M | $-8.72M | $-5.23M | $5.74M | $1.15M | $-6.89M | $16.06M | $5.21M | $11.90M | $-5.45M | $18.82M | $-4.14M | $-12.22M | $-6.93M | $8.02M | $-3.66M |
| Low Forecast | $-913.67K | $-11.66M | $-13.43M | $-21.32M | $-8.31M | $-18.50M | $-19.13M | $-26.68M | $-12.40M | $-27.91M | $-35.45M | $-14.38M | $-26.70M | $-54.06M | $-32.67M | $-13.08M | $-5.31M | $3.82M | $1.15M | $-10.34M | $10.71M | $3.48M | $7.94M | $-8.17M | $12.55M | $-6.21M | $-18.33M | $-10.39M | $5.35M | $-5.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.10% | 11.37% | 3.00% | -10.24% | - | 1.71% | 0.81% | 1.33% | 0.40% | 0.74% | 1.08% | 1.82% | 1.77% | 1.72% | 0.40% | 0.63% |
Tandem Diabetes Care's average Quarter net income forecast for Mar 22 is $-8.61M, with a range of $-10.34M to $-6.89M. TNDM's average Quarter net income forecast represents a -179.70% decrease compared to the company's last Quarter net income of $10.81M (Dec 21).
Tandem Diabetes Care SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 3 | 6 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $79.33M | $97.61M | $89.81M | $97.69M | $84.10M | - | $73.27M | $71.50M | $64.92M | $66.52M | $58.56M | $54.52M | $50.23M | $50.44M | $49.72M | $45.56M | $44.65M |
| Avg Forecast | $133.31M | $120.23M | $118.28M | $106.91M | $118.41M | $106.25M | $104.35M | $94.10M | $107.16M | $95.33M | $87.63M | $139.17M | $86.72M | $82.14M | $84.21M | $126.51M | $94.18M | $53.56M | $87.45M | $100.01M | $88.52M | $48.69M | $61.10M | $79.06M | $50.30M | $27.63M | $28.42M | $28.95M | $46.54M | $70.32M |
| High Forecast | $134.01M | $120.86M | $118.90M | $107.47M | $119.03M | $106.81M | $104.90M | $94.59M | $107.72M | $95.79M | $88.09M | $167.00M | $90.28M | $85.50M | $84.66M | $151.82M | $94.67M | $64.27M | $87.45M | $120.01M | $106.23M | $58.43M | $64.65M | $94.87M | $60.36M | $33.15M | $34.10M | $34.74M | $49.25M | $84.39M |
| Low Forecast | $132.34M | $119.35M | $117.42M | $106.13M | $117.55M | $105.48M | $103.60M | $93.42M | $106.38M | $94.66M | $86.99M | $111.33M | $85.29M | $80.99M | $83.60M | $101.21M | $93.50M | $42.85M | $87.45M | $80.01M | $70.82M | $38.95M | $58.06M | $63.25M | $40.24M | $22.10M | $22.73M | $23.16M | $44.23M | $56.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.97% | 1.16% | 0.71% | 1.04% | 1.57% | - | 0.73% | 0.81% | 1.33% | 1.09% | 0.74% | 1.08% | 1.82% | 1.77% | 1.72% | 0.98% | 0.63% |
Tandem Diabetes Care's average Quarter SG&A projection for Dec 23 is $86.72M, based on 6 Wall Street analysts, with a range of $85.29M to $90.28M. The forecast indicates a 9.31% rise compared to TNDM last annual SG&A of $79.33M (Sep 23).
Tandem Diabetes Care EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 3 | 6 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 11 | 12 | 16 | 9 | 9 | 8 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.51 | $-0.55 | $-1.92 | $-0.25 | $-0.76 | - | $-0.23 | $0.17 | $0.09 | $0.06 | $-0.08 | $0.27 | $-0.15 | $-0.45 | $-0.25 | $0.04 | $-0.05 |
| Avg Forecast | $-0.01 | $-0.18 | $-0.21 | $-0.33 | $-0.13 | $-0.28 | $-0.29 | $-0.41 | $-0.19 | $-0.41 | $-0.54 | $-0.76 | $-0.27 | $-0.48 | $-0.50 | $-0.54 | $-0.08 | $-0.07 | $0.02 | $-0.07 | $0.21 | $0.06 | $-0.08 | $-0.16 | $0.12 | $-0.11 | $-0.24 | $-0.17 | $-0.05 | $-0.20 |
| High Forecast | $-0.01 | $-0.18 | $-0.20 | $-0.32 | $-0.13 | $-0.28 | $-0.29 | $-0.40 | $-0.19 | $-0.34 | $-0.54 | $-0.75 | $-0.18 | $0.03 | $-0.49 | $-0.53 | $-0.08 | $-0.07 | $0.02 | $-0.07 | $0.23 | $0.06 | $-0.08 | $-0.15 | $0.13 | $-0.10 | $-0.22 | $-0.16 | $-0.04 | $-0.19 |
| Low Forecast | $-0.01 | $-0.18 | $-0.21 | $-0.33 | $-0.13 | $-0.28 | $-0.29 | $-0.41 | $-0.19 | $-0.43 | $-0.55 | $-0.77 | $-0.41 | $-0.83 | $-0.50 | $-0.54 | $-0.08 | $-0.07 | $0.02 | $-0.08 | $0.20 | $0.05 | $-0.09 | $-0.17 | $0.11 | $-0.12 | $-0.26 | $-0.18 | $-0.05 | $-0.21 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.10% | 3.57% | 3.08% | 11.53% | - | 3.27% | 0.81% | 1.58% | -0.73% | 0.50% | 2.26% | 1.37% | 1.88% | 1.47% | -0.85% | 0.25% |
According to 9 Wall Street analysts, Tandem Diabetes Care's projected average Quarter EPS for Mar 22 is $-0.07, with a low estimate of $-0.08 and a high estimate of $-0.07. This represents a -141.41% decrease compared to TNDM previous annual EPS of $0.17 (Dec 21).
Tandem Diabetes Care Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NNOX | Nano-X Imaging | $6.32 | $18.00 | 184.81% | Buy |
| ALGN | Align | $243.73 | $554.38 | 127.46% | Buy |
| TNDM | Tandem Diabetes Care | $43.97 | $84.44 | 92.04% | Buy |
| PACB | Pacific Biosciences of California | $1.81 | $3.00 | 65.75% | Buy |
| MDT | Medtronic | $90.00 | $106.77 | 18.63% | Hold |
| DXCM | DexCom | $69.51 | $81.86 | 17.77% | Buy |
| PEN | Penumbra | $186.94 | $218.89 | 17.09% | Hold |
| INSP | Inspire Medical Systems | $203.99 | $237.80 | 16.57% | Buy |
| PODD | Insulet | $233.87 | $268.60 | 14.85% | Buy |
| ABT | Abbott Laboratories | $116.40 | $129.50 | 11.25% | Buy |
| SYK | Stryker | $370.25 | $305.00 | -17.62% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |
TNDM Forecast FAQ
Is Tandem Diabetes Care a good buy?
Yes, according to 14 Wall Street analysts, Tandem Diabetes Care (TNDM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 64.29% of TNDM's total ratings.
What is TNDM's price target?
Tandem Diabetes Care (TNDM) average price target is $84.44 with a range of $36 to $160, implying a 92.04% from its last price of $43.97. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Tandem Diabetes Care stock go up soon?
According to Wall Street analysts' prediction for TNDM stock, the company can go up by 92.04% (from the last price of $43.97 to the average price target of $84.44), up by 263.88% based on the highest stock price target, and down by -18.13% based on the lowest stock price target.
Can Tandem Diabetes Care stock reach $70?
TNDM's average twelve months analyst stock price target of $84.44 supports the claim that Tandem Diabetes Care can reach $70 in the near future.
What are Tandem Diabetes Care's analysts' financial forecasts?
Tandem Diabetes Care's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $992.86M (high $998.1M, low $985.67M), average EBITDA is $-44.955M (high $-44.629M, low $-45.192M), average net income is $-72.124M (high $-71.445M, low $-72.618M), average SG&A $423.1M (high $425.33M, low $420.04M), and average EPS is $-1.11 (high $-1.099, low $-1.117). TNDM's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.12B (high $1.13B, low $1.12B), average EBITDA is $-50.864M (high $-50.496M, low $-51.133M), average net income is $-47.012M (high $-46.57M, low $-47.334M), average SG&A $478.72M (high $481.24M, low $475.25M), and average EPS is $-0.723 (high $-0.717, low $-0.728).
Did the TNDM's actual financial results beat the analysts' financial forecasts?
Based on Tandem Diabetes Care's last annual report (Dec 2022), the company's revenue was $801.22M, which missed the average analysts forecast of $802.02M by -0.10%. Apple's EBITDA was $-30.77M, beating the average prediction of $-11.8M by 160.76%. The company's net income was $-94.594M, beating the average estimation of $-7.962M by 1088.01%. Apple's SG&A was $335.68M, beating the average forecast of $335.2M by 0.14%. Lastly, the company's EPS was $-1.47, beating the average prediction of $-0.2 by 635.21%. In terms of the last quarterly report (Sep 2023), Tandem Diabetes Care's revenue was $281.49M, beating the average analysts' forecast of $192.76M by 46.03%. The company's EBITDA was $-31.545M, beating the average prediction of $-8.728M by 261.44%. Tandem Diabetes Care's net income was $-32.961M, beating the average estimation of $-31.154M by 5.80%. The company's SG&A was $79.33M, missing the average forecast of $82.14M by -3.43%. Lastly, the company's EPS was $-0.51, beating the average prediction of $-0.479 by 6.40%